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Abstract:
Abstract. 
Introduction. The age-related fall in male testosterone levels can have 
clinical consequences. The concentration of serum free testosterone, the 
putative bioactive moiety, is mediated by carrier proteins especially sex 
hormone binding globulin (SHBG). 
Aim. We consider the nature of hormone binding to carriers with new 
insights into determining calculated free testosterone levels and review 
how SHBG and testosterone influence age-related mortality. 
Methods. Where possible we focused on recent literature describing 
binding of testosterone to carrier proteins or, associations between age, 
SHBG, testosterone and mortality. We then used logistic regression to 
study the impact of SHBG and total testosterone on age-related 
mortality in men with type 2 diabetes (T2DM).   
Main outcome measure. The association between mortality and age and 
SHBG and / or total testosterone was determined in a cohort of 364 men 
with T2DM leading to a graphical display of the impact of SHBG / 
testosterone levels on age-related mortality.     
Results.  Low total testosterone and high SHBG are independently 
associated with increased all-cause mortality. Our analyses support 
these findings showing that men with T2DM and a combination of total 
testosterone<12nmol/l and SHBG>35nmol/l (odds ratio (OR): 3.05, 95% 
CI: 1.43-6.53, p=0.004) demonstrated an increased risk of mortality, 
independent of age (OR: 1.08, 95% CI: 1.06-1.11, p<0.001). We 
graphically demonstrated that the risk combination altered the 
relationship between age and mortality. 
Conclusions. Until free testosterone is precisely, accurately and 
conveniently measured, calculated values may provide useful even if 
somewhat inaccurate estimates. We also suggest that SHBG and 
testosterone assays are standardised to allow establishment of 
diagnostic and treatment thresholds. While it is possible the association 
in men with T2DM, between the combination of SHBG and total 
testosterone and age related mortality is driven by free hormone levels, 
it is so far, unproven. 
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Abstract.
Introduction. The age-related fall in male testosterone levels can have clinical 
consequences. The concentration of serum free testosterone, the putative bioactive 
moiety, is mediated by carrier proteins especially sex hormone binding globulin 
(SHBG). 
Aim. We consider the nature of hormone binding to carriers with new insights into 
determining calculated free testosterone levels and review how SHBG and 
testosterone influence age-related mortality.
Methods. Where possible we focused on recent literature describing binding of 
testosterone to carrier proteins or, associations between age, SHBG, testosterone 
and mortality. We then used logistic regression to study the impact of SHBG and 
total testosterone on age-related mortality in men with type 2 diabetes (T2DM).  
Main outcome measure. The association between mortality and age and SHBG 
and / or total testosterone was determined in a cohort of 364 men with T2DM leading 
to a graphical display of the impact of SHBG / testosterone levels on age-related 
mortality.    
Results.  Low total testosterone and high SHBG are independently associated with 
increased all-cause mortality. Our analyses support these findings showing that men 
with T2DM and a combination of total testosterone<12nmol/l and SHBG>35nmol/l 
(odds ratio (OR): 3.05, 95% CI: 1.43-6.53, p=0.004) demonstrated an increased risk 
of mortality, independent of age (OR: 1.08, 95% CI: 1.06-1.11, p<0.001). We 
graphically demonstrated that the risk combination altered the relationship between 
age and mortality.
Conclusions. Until free testosterone is precisely, accurately and conveniently 
measured, calculated values may provide useful even if somewhat inaccurate 
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estimates. We also suggest that SHBG and testosterone assays are standardised to 
allow establishment of diagnostic and treatment thresholds. While it is possible the 
association in men with T2DM, between the combination of SHBG and total 
testosterone and age related mortality is driven by free hormone levels, it is so far, 
unproven.
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Introduction.
The importance, particularly in men with type 2 diabetes (T2DM), of adult 
onset testosterone deficiency (TD), a combination of low serum testosterone and 
symptoms, is illustrated by research showing associations between low hormone 
levels and various pathologies and even mortality. [1] The mechanisms of these 
associations appear to involve serum proteins that transport testosterone and 
mediate the amounts of hormone that are in free solution or bioavailable. Serum sex 
hormone binding globulin (SHBG) has attracted particular attention as it appears 
critical in determining the serum level of these moieties which have been proposed 
as determinants of androgen activity (Figure 1). [2] Due to continuing uncertainties 
regarding some testosterone and SHBG assays and methods used to determine free 
and bioavailable testosterone, it seems clear that gaining a better understanding of 
the relationship between the hormone, SHBG and clinical phenotypes should help 
improve the diagnosis and management of men with symptoms of hypogonadism. 
We firstly review data describing the clinical importance of maintaining 
adequate levels of testosterone and secondly consider the nature of hormone 
binding to its carriers and methods to estimate free and bioavailable testosterone. 
We thirdly, review studies indicating that SHBG is a clinically useful marker focusing 
on the finding that SHBG is independently associated with mortality in men with 
T2DM. Since age is strongly associated with mortality and SHBG and, appears to 
mediate the impact of SHBG and testosterone on mortality, we describe further 
analysis of data from our published study showing the impact of combinations of 
these predictors on the probability of age-related mortality. [3] The combination of 
low total testosterone and high SHBG in men aged>66 years is a principal risk 
category.  
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Clinical Importance of testosterone.
Testosterone has varied functions in humans, perhaps the best recognized 
being in development of the male reproductive system [4]. Some of its other 
pleiotropic functions may become evident in older men as serum levels typically 
decline by about 30% between ages 40-90 years [5,6,7,8,9]. Thus, symptoms of 
adult onset TD may include decreases in bone mineral density, muscle strength, 
cognitive and sexual function.[4,5,6,7,8,9] Adult onset TD is also associated with 
increased central obesity and insulin resistance and consequently, the metabolic 
syndrome (MetS) and T2DM. [4,10,11,12,13,14,15,16] The prevalence of adult onset 
TD is high in T2DM and MetS patients; in our cohort about 70% of men with T2DM 
had low serum total testosterone levels (<12nmol/L) and sexual symptoms [12] 
though other studies have shown a lower prevalence of up to 40%. [13,17] 
Importantly, both adult onset TD and erectile dysfunction are independently 
associated with increased mortality [18,19,20] and, T2DM is linked with 
cardiovascular disease (CVD), sexual dysfunction and reduced life expectancy. [16]
Independent studies show an association between low serum testosterone 
and adverse CVD events and all-cause mortality. [21,22,23,24,25,26,27,28] For 
example, the European Male Ageing study (2599 men, 7% withT2DM, aged 40-79 
years) showed that adult onset TD with total testosterone <8nmol/l was significantly 
associated with increased total and CVD-related mortality [22]. That the reduced 
availability of testosterone is a causative factor is supported by data showing 
testosterone replacement (TTh) can lead to improved sexual health and reduced all-
cause mortality [6,19,23,24,25]. Shores et al showed TTh was associated with 
significantly reduced mortality in men with T2DM aged over 40 years and with total 
testosterone ≤8.7nmol/l but not in non-diabetic counterparts.[24] This finding was 
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confirmed by 2 longitudinal studies; Muraleedaran et al studied the effects of low 
testosterone (<10.4 nmol/l) and TTh on mortality in 581 men with T2DM. [6] After 
adjustment for confounders, mortality was higher in the low testosterone group. 
Further, the 174 men not on TTh were at significantly higher risk of mortality than the 
64 men receiving TTh. We found similar results in 857 men with T2DM using a total 
testosterone cut-off of 12.0 nmol/l and free testosterone of 0.25 nmol/l. [19,25]. 
Compared with men with low total or calculated free testosterone and not on TTh, 
mortality was lower in men with normal testosterone (Hazard Ratio (HR): 0.62, CI: 
0.41 - 0.94) and men with low testosterone on TTh (HR: 0.38, CI: 0.16 - 0.90). This 
benefit was independent of changes in cardiovascular/metabolic risk factors [29]. 
These data show that low serum testosterone levels have clinical implications, 
and accordingly, serum total and free testosterone treatment thresholds for TTh are 
identified; guidelines issued by the British Society for Sexual Medicine have 
indicated that men with total testosterone<8nmol/l or free testosterone<0.180nmol/l 
usually require TTh while those with total testosterone 8-12nmol/l may require TTh 
depending on symptoms [30]. However, the relationship between extent of reduction 
in serum testosterone and particular clinical symptoms is unclear and, the 
establishing of universal, clinically useful cut-off values is problematic. Firstly, an 
assay standardisation approach may be required as marked between-method 
variation in the accuracy and precision of SHBG and testosterone assays has been 
identified (https://birminghamquality.org.uk/eqa-programmes/ster/ - accessed 
20/05/2019) [31] and secondly, none of the commonly used guidelines include 
corresponding values for variables such as SHBG that mediate free testosterone 
levels.
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Sex Hormone Binding Globulin
Hydrophobic steroids such as testosterone are largely transported in serum 
by carrier proteins including SHBG and albumin. [32,33]. SHBG is central because 
its ability to bind testosterone mediates transport, serum levels of free/bioavailable 
and cellular uptake of testosterone and appears to offer in some men, a clinically 
useful insight into androgen status. [2,32,33,34,35] 
SHBG, a homodimeric glycoprotein, is largely synthesised in the liver. [2] 
Each monomer has one steroid binding site allowing transport of two steroid 
molecules/dimer. In serum, SHBG binds steroids such as dihydrotestosterone and 
testosterone with high affinity; Ka~109 l/mol while albumin, present in human serum 
at high concentration (typically ~40 g/l) offers substantial capacity but low affinity (Ka; 
~3X104 l/mol). [35,36,37,38,39] Cortisol binding globulin (Ka 5.3X106 l/mol) and 
orosomucoid (Ka 3.0X105 l/mol) also bind the steroid weakly. [32,38,39,40,41] 
Accordingly, they often ignored in the context of testosterone and phenotype.
Serum SHBG, total and free/bioavailable testosterone 
Various algorithms have been used to calculate free or bioavailable 
testosterone. [38,39,40,41] The widely used Vermeulen et al model is based on 
mass-action binding and assumes one molecule of testosterone binds to one SHBG 
molecule [38]. Other more recent models are based on each SHBG monomer having 
a binding site that can receive one testosterone molecule. [42] 
Figure 1 shows, for 3 total testosterone concentrations (median, 25% and 75% 
percentile of our cohort of men with T2DM) [19] how changes in SHBG mediate 
levels of calculated bioavailable and free testosterone. By changing SHBG values 
within the observed distribution in men with T2DM, the free testosterone 
concentration can fall considerably when SHBG increases from the 25th to 75th 
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percentile. For serum albumin, a protein that usually demonstrates much less 
variation, the extent of change in free testosterone is modest (data not shown). Thus, 
even allowing for possible errors in the binding parameters and, differences in the 
approaches used to derive the algorithms, it may be reasonable to consider values 
of free or bioavailable testosterone in “local units” as showing patterns of change. 
Because of its high serum concentration, barely 1% of albumin binding sites in 
men are generally occupied while for SHBG, 36% of sites are occupied by 
testosterone, 20% by androgen metabolites or oestradiol and only 44% are 
unoccupied. [36] Dunn et al proposed that SHBG largely determines the serum 
distribution of sex steroids and that changes in its level will alter testosterone 
distribution [36]. 
Albumin-bound testosterone may also be bioavailable because binding is 
weak and interactions with the vascular wall may allow dissociation of steroid during 
flow through capillaries. [43,44]. Bioavailable may be a more useful measure of 
hormone status than total testosterone; for example, its fall during male aging is 
steeper and associated with features of adult onset TD. [45,46,47,48]
Issues in Quantifying Free and Bioavailable testosterone. 
Determination of free or bioavailable testosterone experimentally or using 
algorithms is relatively demanding because of inter- and intra-laboratory imprecision 
of available methods and different values for binding parameters. Discrepancies 
between free testosterone values calculated using the Vermeulen et al approach and 
a variety of other algorithms or determined experimentally are reported. [37,38, 
42,49,50,51,52] Recently, Zacharov et al proposed a more complex model of 
testosterone binding. [53] Thus, while it had been believed that testosterone 
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associated to each SHBG site with the same affinity, Zacharov et al proposed that 
testosterone binding to one monomer affects the interaction of the next testosterone 
molecule with the unoccupied, second site and the second molecule is bound with a 
different affinity to the first indicating the process is allosteric. [53] Zakharov et al 
argued that SHBG binding of testosterone cannot be described by available 
algorithms and instead used an allosteric model to calculate free testosterone. [53] In 
samples from Framingham Heart Study subjects, levels calculated using a traditional 
algorithm were markedly lower than those obtained using an allosteric model; in 
subjects aged<30 years, free testosterone using a traditional model was 
145.35±45.8 (SD) pg/ml and the allosteric model, 238.339±71.77 (SD) pg/ml. The 
allosteric model gave values similar to those obtained using equilibrium dialysis. 
[42,53] 
While there is no universally accepted method for determining free and 
bioavailable testosterone, an international expert consensus conference in 2015 
stated that this analysis was important in the assessment of men with adult onset TD 
[54]. As clinicians (SR, GIH), we agree and consider free testosterone together with 
SHBG and total testosterone integral in routine patient screening and monitoring. 
Free testosterone measurements are particularly useful in the investigation of men 
with adult onset TD symptoms and a borderline total testosterone of 8-11 nmol/l, 
though perhaps less so in men with total testosterone<8 nmol/l. [55,56] 
 
SHBG: Wide range of values in human serum 
The symptoms and characteristics of hypogonadism are nonspecific and 
varied and not always associated with low testosterone levels prompting interest in 
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the relationship between SHBG (as an independent variable) and clinical phenotype 
[57]. While SHBG may not have a direct effect on clinical outcomes we might expect 
higher serum SHBG levels to be associated with greater morbidity/mortality as 
free/bioavailable testosterone levels would presumably be lower. Thus, increased 
SHBG causes decreased free testosterone, triggering luteinizing hormone release 
and increased testosterone production until free hormone levels are restored. An 
insight into the biological importance of SHBG may be gained by considering 
individuals who have no peptide. Vos et al described an extremely rare missense 
mutation that encoded a secretion defective SHBG variant that accumulated in cells. 
[58] A brother and sister, homozygotes for the mutant allele, had no detectable 
serum SHBG. In the brother, serum total testosterone levels were low but free levels 
appeared adequate. Gonadal development and sperm production and function 
appeared normal though he had symptoms of hypoandrogenism. The sister reported 
a late menarche and irregular menstrual cycles. These findings suggest SHBG is 
required for some of testosterone’s anabolic activities but is not essential for male 
reproductive development [58]. 
It is noteworthy that considering a physiological role for SHBG is not helped 
by the finding that its serum concentrations vary during life and demonstrate marked 
inter- and intra-individual variation even in apparently healthy adults. [2] For 
example, Krakowsky et al [34] found a mean SHBG concentration in 1000 
consecutive patients of 31.8±15.2 nmol/l (range 6-109 nmol/l) while we found in 857 
men with T2DM, concentrations between 7.9 - 185.5 nmol/l [59]. Further, during 
adulthood, SHBG levels increase with age though there is a wide variation in 
individuals stratified by young/old age. [34,59] 
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SHBG level and clinical phenotype. 
Much research shows the importance of SHBG in determining clinical 
phenotype. [3,57,59,60,61,62,63,64] For example, the European Male Aging Study 
showed men with normal total but low free testosterone (using the algorithm of 
Vermeulen et al [38]) had higher LH levels, more sexual and physical symptoms than 
men with normal total and free testosterone or men with low total and normal free 
testosterone levels. [21] Thus, low free testosterone, even with a normal total 
testosterone, was associated with adult onset TD, while low total testosterone with 
normal free was not. Studies in transgenic mice that overexpressed SHBG also 
show that androgen deficiency is apparent in individuals with normal or borderline 
levels of serum total testosterone. [61]
Many factors mediate serum peptide levels; hormones including thyroxine, 
insulin, insulin like growth factor-1, prolactin and, non-hormonal factors including 
physical activity, body weight, body-mass-index (BMI), waist-to-hip ratio, some drugs 
and diet modify SHBG levels. [2,59] SHBG levels are lower with increasing obesity 
and in patients with T2DM and a low level of SHBG is associated with increased risk 
of developing MetS, gestational diabetes and T2DM and the cardiovascular disease 
linked with these conditions. Furthermore, SHBG genetic variation has been 
proposed to contribute to the development of T2DM. 
The above data raise issues of how closely serum SHBG levels are regulated 
and which of the varied factors that affect expression are most important. [65] 
Gyawali et al in a cross-sectional and longitudinal study identified various 
determinants of serum SHBG in men. [66] Baseline SHBG levels were positively 
associated with age, thyroxine and total testosterone and inversely with abdominal 
fat mass, triglycerides and oestradiol. Low SHBG levels largely reflect obesity. It was 
Page 11 of 32
Sexual Medicine Reviews
Sexual Medicine Reviews
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
suggested that variation in SHBG reflects de novo hepatic lipogenesis and insulin 
resistance and that thyroid hormone may modulate circulating SHBG. High levels of 
serum sex steroids are associated with higher SHBG levels. [66]
SHBG: An independent factor determining mortality?
A range of metabolically active factors influence serum SHBG levels many of 
which are risk factors for clinically important phenotypes. Accordingly, establishing 
the independence of associations between SHBG and patient characteristics is 
important.  
Recently, Tint et al [60] showed that elevated levels of SHBG and low levels 
of free testosterone were significantly and independently associated with all cause-
mortality after adjustment for diabetes-related risk factors. The association of total 
testosterone with mortality weakened after such adjustment. We also investigated 
the impact of SHBG, age and related variables on mortality in 364 men with T2DM. 
[3] Age, SHBG and testosterone were significantly and independently associated 
with mortality. SHBG was associated with age, testosterone, statin use and MetS 
features. Mortality rate and age increased with SHBG quartiles. When pairwise 
combinations of age and SHBG dichotomized by median values were considered, 
the association of SHBG with mortality was age-dependent; firstly, age >66 
years/SHBG >35 nmol/l was significantly associated (HR: 9.37, p<0.001) with 
greater mortality (22.45%) compared to age ≤66 years/SHBG ≤35 nmol/l (mortality: 
3.23%) and secondly, SHBG ≤35 nmol/l was associated with decreased mortality in 
men >66 years (HR: 0.41, p=0,037, reference: SHBG > 35 nmol/l) but in men ≤66 
years there was no significant difference in those with SHBG >35 nmol/l (HR:1.73, 
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p=0.56, reference: SHBG ≤ 35 nmol/l). By contrast, total testosterone<12 nmol/l was 
significantly associated with increased mortality in both age groups. Thus, while the 
association of SHBG with mortality in T2DM men is mediated by age, that with total 
testosterone<12 nmol/l was found irrespective of age < or >66 years.
These analyses demonstrate the cumulative effects of the risk phenotypes; 
age>66 years, total testosterone<12 nmol/l and SHBG>35 nmol/l. Men with two of 
factors demonstrated high mortality; age>66 years/SHBG>35 nmol/l: mortality 22.5% 
and age>66 years/total testosterone<12 nmol/l: mortality 25.0%. In men with all three 
risk variables, age>66 years/total testosterone<12 nmol/l/SHBG>35 nmol/l, mortality 
was 36.8%. Thus, SHBG is linearly associated with age but its association with 
mortality is more evident in men aged>66 years (who also suffer higher mortality). In 
men with T2DM, the combination of low total testosterone, high SHBG and age> 66 
years is a principal risk category compared with other combinations. [3]
SHBG, testosterone and age-related mortality. 
As both SHBG and mortality increase with age while both total and free 
testosterone levels fall (https://uroweb.org/wp-content/uploads/EAU-Guidelines-
Male-Hypogonadism-2015.pdf -  accessed on 20/05/2019) establishing prognosis 
(eg. mortality) in individual patients is difficult. One approach that demonstrates the 
association of inter-related variables with mortality at different ages is based on 
Benjamin Gompertz’s observations that mortality increases exponentially with age. 
[67,68,69], More recently we found in our cohort of men with T2DM that the 
relationship between age and mortality was as described by Gompertz. [25] 
To determine how SHBG and testosterone influence age-related mortality in 
T2DM men who had not received TTh we determined the probability of each of the 
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previously described 364 men with T2DM categorised by SHBG or testosterone, 
living or dying at a particular age. [3] We used a logistic regression model to derive 
the probability of mortality (dependent variable) with age (continuous variable) and 
SHBG and/or testosterone (dichotomized) as independent variables. Probability of 
mortality and 95% confidence intervals were plotted against age. If no overlap of the 
95% confidence intervals between treatment/no treatment lines was observed, we 
considered the treatment significantly altered the relationship between age and 
mortality. The approach allows a graphic demonstration of the impact of stratified 
levels of SHBG and/or testosterone (stratified by median values; SHBG 35nmol/l, 
total testosterone 12nmol/l) on mortality over a range of ages. Since age is the most 
significant predictor of death, finding that a variable alters this relationship gives an 
indication of its biological importance. The regression analyses (Table 1) were 
carried out sequentially, building with each successive model on the previous 
analysis. We ended with mortality as the dependent variable and age and a 
dichotomised combination of SHBG and total testosterone as independent variables 
(model 8). None of these men had received TTh and, accordingly, median values for 
SHBG (35nmol/l) and total testosterone (12nmol/l) are different from previous 
distributions where baseline values of the total cohort that included men who 
received TTh were used.
In logistic regression analyses we showed that individually, age (Model 1) and 
age and SHBG entered as independent variables (model 2) were significantly 
associated with mortality. When total testosterone was entered (with age) it was not 
significantly associated with mortality (model 3) though in an analysis (model 4) 
comprising all three variables, each was independently, significantly associated with 
mortality. As expected, increasing age and SHBG were associated with increased 
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mortality with total testosterone inversely associated with mortality. Dichotomizing 
SHBG and total testosterone by their median values showed SHBG>35 nmol/l and 
total testosterone<12 nmol/l were individually and independently significantly 
associated with increased mortality (model 4). We then further studied the 
association between SHBG and mortality in men stratified by the median total 
testosterone of 12nmol/l. Interestingly, the association of SHBG >35 nmol/l with 
mortality was not observed in men with testosterone ≥12 nmol/l (Model 6b) unlike in 
men with total testosterone < 12nmol/l (Model 6a). Accordingly, we used 
combinations of SHBG and total testosterone (model 7) with age as independent 
variables and found men with total testosterone<12nmol/l and SHBG>35nmol/l 
(reference) were at risk compared to the other 3 combinations. Model 8 shows that 
relative to other combinations of SHBG and testosterone, men with SHBG>35 nmol/l 
and testosterone<12 nmol/l had the highest mortality risk. The model was used to 
calculate the probability of death and 95% confidence intervals for each man. Figure 
2 shows the association between probability of mortality and age in these two 
groups. Mortality is greater in men with the combination of SHBG >35nmol/l and 
testosterone<12 nmol/l though there is some overlap of 95% CI values after about 69 
years indicating that, despite relatively small patient numbers, the combination of 
elevated SHBG and low total testosterone alters the relationship between age and 
mortality.
Conclusions
A paradox is apparent. While it is noteworthy that SHBG and T2DM and the 
MetS are positively associated with mortality, both conditions are negatively 
associated with SHBG. Thus, while high levels of SHBG are associated with 
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increased all-cause mortality, levels of the peptide are inversely associated with 
insulin resistance and this may mediate the association between low serum 
testosterone and increased mortality in men with T2DM. [3,6,19,60,70] 
Both SHBG and low total testosterone are identified as independent variables 
that mediate age-related mortality in men with T2DM. The more limited data 
available for free testosterone derived using a traditional algorithm are supportive of 
these findings. In a T2DM context free/bioavailable testosterone is integral in the 
development of disease phenotypes including mortality; low free testosterone was 
associated with mortality more strongly than either total testosterone or SHBG. [60] 
Clearly, apart from inter-individual variation in SHBG and testosterone levels, other 
host characteristics such as androgen sensitivity and the functionality of androgen 
receptors are potential factors affecting outcome. [71,72] 
A further complication may be reports indicating SHBG acts as more than just 
a carrier protein in specific instances. It has also been suggested that SHBG could 
affect mortality by a mechanism that is independent of its role in testosterone 
metabolism such as regulation of cell proliferation. [42,74] These data remain to be 
assessed.
This review has demonstrated associations between SHBG and clinical 
phenotypes with particular focus on mortality. While the mechanism is uncertain, it 
might be speculated that the association is determined by the actions of the globulin 
in determining serum levels of free/bioavailable testosterone. However, the 
association of SHBG with mortality is independent of free and total hormone perhaps 
hinting at further functions of the globulin and/or the need for better methodologies to 
quantify these analytes and/or a role for other steroid hormones transported by 
SHBG. [31,42,73,74,75,76] 
Page 16 of 32
Sexual Medicine Reviews
Sexual Medicine Reviews
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Given the association of SHBG with mortality, it is tempting to speculate on 
the feasibility and usefulness of clinical modification of serum globulin levels. Given 
the association of SHBG with mortality, it is tempting to speculate on the feasibility 
and usefulness of clinical modification of serum globulin levels. A wide range of 
factors including widely used drugs such as statins, mediate SHBG levels. For 
example, in men with T2DM, Stanworth et al. showed that atorvastatin therapy (but 
not simvastatin) was associated with significantly reduced total testosterone and a 
trend towards reduced SHBG levels and we reported that statin therapy was 
associated with a significant reduction in SHBG levels. [3,77] 
Alternatively, vegetarian, vegan and low calorie diets may be associated with higher 
serum SHBG concentrations though changes in testosterone levels have varied 
between studies. [78] It is not known if any of these approaches have clinical 
relevance in the context of adult onset TD and, in our view use of therapy to modify 
SHBG levels is, given current uncertainties, inappropriate. 
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Figure 1. Calculated free testosterone and bioavailable testosterone levels at median (32.5 nmol/l) and inter quartile range (24.2 / 
45.1 nmol/l) of SHBG and median (11.4 nmol/l) and inter quartile range (8.3 nmol/l / 14.8 nmol/l) of total Testosterone 
concentrations in men with T2DM [19]
Calculated free testosterone and bioavailable testosterone levels were estimated using the algorithm by Vermeulen et al [26] with 
albumin concentrations at a default value of 43g/l.
Other proteins (CBG / orosomucoid) are not included in the figure as they are not included in the Vermeulen algorithm. 
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Figure 2: Association between probability of mortality and age. Estimated mortality probability and 95%CI (in men with T2DM 
between 65 – 80 years) from the fitted logistic regression (Table 1) was calculated from the logistic regression analysis (Model 8) 
and plotted against age at death or final visit.
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Table 1: Logistic regression models showing association between age and mortality (dichotomous dependent variable) in men with 
T2DM in the presence of SHBG and / or TT (either as continuous variables or stratified categories) in the total cohort (Models 1, 2, 
3, 4, 5, 7 and 8) or when stratified by TT of 12 nmol/l (Models 6a, 6b).  
 OR (95% CI) p
Model 1, n=364   
Age (years) 1.10 (1.07-1.13) <0.001
Model 2, n=364   
Age (years) 1.10 (1.05-1.14) <0.001
   
SHBG (nmol/l) 1.02 (1.00-1.03) 0.015
Model 3, n=362   
Age (years) 1.10 (1.06-1.15) <0.001
   
TT (nmol/l) 0.97 (0.91-1.04) 0.38
Model 4, n=362   
Age (years) 1.08 (1.04-1.13) <0.001
   
SHBG (nmol/l) 1.03 (1.01-1.05) 0.001
TT (nmol/l) 0.91 (0.85-0.98) 0.015
Model 5, n=362   
Age (years) 1.08 (1.04-1.13) <0.001
   
SHBG ≤ 35 nmol/l reference  
SHBG > 35 nmol/l 2.54 (1.14-5.66) 0.022
   
TT <12 nmol/l reference  
TT ≥ 12 nmol/l 0.37 (0.17-0.81) 0.013
Model 6a (TT < 12nmol/l), n=181   
Age (years) 1.09 (1.03-1.15) 0.001
   
SHBG ≤ 35 nmol/l reference  
SHBG > 35 nmol/l 2.83 (1.15-6.97) 0.023
Model 6b (TT ≥ 12nmol/l), n=181   
Age (years) 1.09 (1.03-1.16) 0.006
   
SHBG ≤ 35 nmol/l reference  
SHBG > 35 nmol/l 1.75 (0.36-8.37) 0.49
Model 7   
Age (years) 1.09 (1.05-1.14) <0.001
   
SHBG > 35 nmol/l / TT < 12 nmol/l reference  
SHBG ≤ 35 nmol/l / TT < 12 nmol/l 0.35 (0.14 - 0.86) 0.022
SHBG ≤ 35 nmol/l / TT ≥ 12 nmol/l 0.19 (0.04 - 0.95) 0.043
SHBG > 35 nmol/l / TT ≥ 12 nmol/l 0.34 (0.14 - 0.80) 0.013
Model 8   
Age (years) 1.08 (1.06-1.11) <0.001
   
SHBG > 35 nmol/l / TT < 12 nmol/l 3.05 (1.43 - 6.53) 0.004
Remaining groups reference  
SHBG ≤ 35 nmol/l / TT < 12 nmol/l   
SHBG ≤ 35 nmol/l / TT ≥ 12 nmol/l   
SHBG > 35 nmol/l / TT ≥ 12 nmol/l   
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Figure 1. Calculated free testosterone and bioavailable testosterone levels at median (32.5 nmol/l) and inter 
quartile range (24.2 / 45.1 nmol/l) of SHBG and median (11.4 nmol/l) and inter quartile range (8.3 nmol/l / 
14.8 nmol/l) of total Testosterone concentrations in men with T2DM [19] 
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Figure 2: Association between probability of mortality and age. Estimated mortality probability and 95%CI 
(in men with T2DM between 65 – 80 years) from the fitted logistic regression (Table 1) was calculated from 
the logistic regression analysis (Model 8) and plotted against age at death or final visit. 
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